Avalo Therapeutics, Inc.
AVTX · Healthcare · $341M mkt cap · FY2025 filings · · not refreshed in 35 days · No moat ·
Price verdict withheld — value if growth stopped today unreliable
The five investor questions
2022–2025 (latest 4 aligned FYs; v3 window cap 5): revenue $18.1M to $59000, decreasing; diluted EPS -1063.00 to -5.84, increasing. Latest-filed diluted EPS remains usable for Business Trend, but an integer share-count change lacks enough evidence to confirm a comparable EPS basis; valuation growth therefore stays at 0%.
Median gross margin 88.2% over 8y, variable.
Median ROIC -85.7%, above the 12% hurdle in 20% of years.
Net cash position — no leverage risk.
Owner earnings changed trend unclear over up to the ten most recent annual observations, share count n/a.
Price vs. value if growth stopped today
A cautious baseline, not a price target: what the shares may support if normalized owner earnings simply hold steady.
- Not reported
- Unavailable — insufficient owner-earnings data
- Unavailable — insufficient growth-model data
- $18.44
- No price data
This zero-growth estimate assumes trailing owner earnings persist — unreliable for declining businesses. AVTX revenue fell in each of the three most recent year-over-year FY comparisons, so this estimate is flagged as unreliable for this company.
Among the current top-score group, the median current price is 239% above the zero-growth estimate across 48 of the current top 50 companies by Moat Score with both values.
Score records captured Jul 26, 2026.
Exactly which 50 companies?
FTNT, META, MEDP, IBEX, MSFT, GOOGL, LULU, ANF, IDXX, TXRH, FHI, QLYS, FFIV, ADBE, LLY, MANH, VEEV, GRMN, SSD, MNST, DOCS, MCO, CPRT, NTAP, LRCX, NVDA, CORT, SFM, MPTI, ULTA, SN, RMD, ROL, PAYC, IRMD, INTU, DECK, MORN, LGCY, DAL, GWW, ISRG, MPWR, CTAS, LOPE, MRK, CMG, FAST, BKNG, ORLY
Missing a usable price or zero-growth estimate: ANF, BKNG.
Model details under moat-index@3.0.0: zero-growth multiple 11.1×, capped-growth comparison at no more than 18×; 9% discount rate; high-end growth 0% (capped at 4%) using min(5y revenue CAGR, 5y diluted-EPS CAGR), clamped to 0%–4%; maintenance capex uses min(capex, D&A); abstain when D&A is unavailable. This is a disclosed model range, not intrinsic value as fact.
14 years of fundamentals
The business, in plain English
It earned −85.7% on invested capital in the latest filed year, FY2025. Across the full 5-year measurable filed record, median ROIC was −85.7%. Over the v3 recent window (5 measurable filed years), median ROIC was −85.7%. The Returns on Capital filter above scores it 7/100.
AVTX's latest filed year, FY2025, doesn't disclose total debt in a form the methodology can use, so current leverage is treated as unmeasured — never assumed to be zero.
Put together: Pricing Power is the strongest of the five filters (70/100) and Returns on Capital the weakest (7/100), which is how AVTX lands at 39/100 — a None moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Not meaningful FY2014–2016: invested capital is negative (cash exceeds debt + equity)
The explained ROIC gaps have filed inputs but no meaningful positive invested-capital denominator. Other gaps mean the item is not in the filings for that year. The series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Visual explainers
The filing-backed explainer service is temporarily unavailable, so no partial or guessed chart is shown.
Moat Score history
Breaks in the line mark methodology or normalizer upgrades — readings across versions aren’t compared, so a level shift there isn’t a change in the business.
Tier changesSame-methodology and same-normalizer crossings of the Wide / Narrow / Shallow bars
- Normalizer upgraded unstamped (version unknown)tomoat-xbrl-normalizer@1.1.0 — readings across versions aren’t comparedJul 26, 2026
- Methodology upgraded moat-index@2.0.0tomoat-index@3.0.0 — readings across versions aren’t comparedJul 23, 2026
- Methodology upgraded moat-index@1.2.0tomoat-index@2.0.0 — readings across versions aren’t comparedJul 20, 2026
Scores are logged append-only and never overwritten — this record cannot be reconstructed retroactively, which is exactly why it’s worth keeping.
Insider activity
Form 4 reports mix P/S market or private transactions with compensation-plan mechanics. Activity casually described as “insider selling” can include compensation mechanics; awards, tax withholding, and option exercises are shown by their exact filed class here, never collapsed into “Bought” or “Sold.”
These are disclosed filing facts and arithmetic aggregates, not a signal or verdict.
The insider-filing service is temporarily unavailable, so no partial or guessed answer is shown for AVTX.
Healthcare context
#377 of 710 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #375MD Pediatrix Medical Group, Inc.39.2 out of 100, No moatNo moat
- #376ISCO INTERNATIONAL STEM CELL CORPORATION39.2 out of 100, No moatNo moat
- #378SEPN Septerna, Inc.39.2 out of 100, No moatNo moat
- #379RSCF REFLECT SCIENTIFIC, INC.39.1 out of 100, No moatNo moat
Compare AVTX with its nearest peers →All Healthcare companies on the Index →
Common questions about AVTX
- Does Avalo Therapeutics, Inc. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores Avalo Therapeutics, Inc. (AVTX) 39.2 out of 100 — below the Shallow-moat bar, so no moat. The five questions behind that score begin at 20% each; if exactly one genuinely lacks data, the other four weights are renormalized and disclosed. revenue and EPS trend 20, pricing power 70, returns on capital 7, balance-sheet safety 55, capital allocation 44.
- How has AVTX's Moat Score changed over time?
- The record logs 16 readings since Jul 17, 2026; the latest reads 39.2 out of 100 (no moat). No tier changes on record yet. (Methodology or normalizer upgrades on Jul 20, 2026, Jul 23, 2026, Jul 26, 2026 re-based the score; readings across versions aren't compared.) The history is append-only — readings are only ever added, never rewritten.